Douglas Carl Fisher - Oct 8, 2021 Form 4 Insider Report for PHOENIX BIOTECH ACQUISITION CORP. (PBAX)

Role
President
Signature
/s/ Chris Ehrlich, as attorney-in-fact
Stock symbol
PBAX
Transactions as of
Oct 8, 2021
Transactions value $
$0
Form type
4
Date filed
10/12/2021, 07:31 PM
Previous filing
Oct 5, 2021
Next filing
Mar 31, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PBAX Class A common stock Other +10K 10K Oct 8, 2021 By Phoenix Biotech Sponsor, LLC F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PBAX Class B Common Stock Other +100K 100K Oct 8, 2021 Class A Common Stock 100K By Phoenix Biotech Sponsor, LLC F1, F3, F4
transaction PBAX Warrants Other +5K 5K Oct 8, 2021 Class A Common Stock 5K $11.50 By Phoenix Biotech Sponsor, LLC F1, F3, F5, F6, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Allocated to the reporting person as a member of Phoenix Biotech Sponsor, LLC.
F2 These shares underlie 10,000 units of the issuer purchased by the reporting person.
F3 Held directly by the issuer's sponsor, Phoenix Biotech Sponsor, LLC, of which the reporting person is a member. The reporting person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for any other purpose.
F4 The shares of Class B common stock will automatically convert into shares of Class A common stock at the time of the issuer's initial business combination on a one-for-one basis, subject to certain adjustments described in the issuer's charter documents and have no expiration date.
F5 These warrants underlie 10,000 units of the issuer purchased by the reporting person.
F6 The warrants will become exercisable at the later of 30 days after the consummation of the issuer's initial business combination or 12 months from the completion of the issuer's initial public offering.
F7 The warrants will expire five years after the consummation of the issuer's initial business combination or earlier upon redemption of all of the issuer's outstanding Class A common shares or the issuer's liquidation.